iSpecimen Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 88/100
What the filing says
iSpecimen completed acquisition of two AI products from Foldlab AI Ltd. on November 2, 2026: a Disease-Associated Protein Discovery AI Agent and Disease Trend Prediction/Monitoring AI Model. Total consideration: $750,000 cash at closing, up to $1.25M in two $625K milestone payments, and $2.5M in common stock (2,907,977 shares at VWAP, issued November 5, 2026). Stock subject to 5-year lock-up, no-leak-out, and voting restrictions; Foldlab retains all economic rights during restriction period.
Why this rating
Transformational for $2.4M-cap company: $4.5M deal equals ~188% of market cap, diversifies revenue, enters AI/software market, materially expands addressable market beyond biospecimens.
Tradability signal
NO TRADE
No trade: only ~$67k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.79 ▼ 3.05% | at our read · unknown $0.82 | +10 min · unknown $0.79 ▼ 4.14% | +30 min · unknown $0.80 ▼ 2.34% | +1 hr · unknown $0.83 ▲ 0.79% | +4 hrs · unknown $0.82 ▼ 0.06% |
The stock had already moved +3.15% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.